Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04445688 · ClinicalTrials.gov registry record · Phase 2
Crossover Trial of AD036 in Obstructive Sleep Apnea
A Phase 2 study, sponsored by Apnimed.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT04445688 is a Phase 2 study that has completed, run by Apnimed. The registered enrollment target is 62 participants.
The verdict
NCT04445688, a Phase 2 study, has completed, sponsored by Apnimed.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
This is a randomized, 3-Period, Placebo-Controlled, Crossover, phase 2 clinical study to examine the efficacy and safety of AD036 versus placebo or atomoxetine in patients with obstructive sleep apnea.
Interventions
- DRUG Placebo
- DRUG Atomoxetine
- DRUG AD036
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2020-07-15 |
| Est. Completion | 2020-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04445688
The ClinicalTrials.gov registry entry for NCT04445688 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Apnimed, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04445688 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04445688 about?
NCT04445688 is a clinical study titled "Crossover Trial of AD036 in Obstructive Sleep Apnea". This is a randomized, 3-Period, Placebo-Controlled, Crossover, phase 2 clinical study to examine the efficacy and safety of AD036 versus placebo or atomoxetine in patients with obstructive sleep apnea.
What is the current status of trial NCT04445688?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2020-07-15. Estimated completion is 2020-12-01.
What interventions are being tested in trial NCT04445688?
The interventions under investigation include: Placebo (DRUG), Atomoxetine (DRUG), AD036 (DRUG).
Who is sponsoring clinical trial NCT04445688?
This trial is sponsored by Apnimed, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.